[Translation] A single-arm, open-label, multicenter Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic characteristics, and efficacy of 3D-197 monotherapy in subjects with locally advanced or metastatic solid tumors and relapsed or refractory hematological tumors
评估3D-197单药在局部晚期或转移性实体瘤和复发或难治性血液肿瘤受试者中的安全性和耐受性;
确定 3D-197 的 II 期推荐剂量(RP2D)
[Translation] Evaluate the safety and tolerability of 3D-197 monotherapy in subjects with locally advanced or metastatic solid tumors and relapsed or refractory hematological tumors;
Determine the Phase II recommended dose (RP2D) of 3D-197